BioMarin cutting about 170 jobs after shuffling drug portfolio

The cuts are the latest stemming from an agreement last year with an activist shareholder aimed at maximizing BioMarin’s long-term value.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks